Advertisement
Pharmacotherapy Original research| Volume 34, ISSUE 10, P2082-2090, October 2012

Safety of Exenatide Once Weekly in Patients With Type 2 Diabetes Mellitus Treated With a Thiazolidinedione Alone or in Combination With Metformin for 2 Years

      Abstract

      Background

      Patients with type 2 diabetes mellitus are routinely treated with combinations of glucose-lowering agents. The adverse event (AE) profile and effects on glycemic control have not been assessed for the glucagon-like peptide-1 receptor agonist exenatide once weekly in combination with a thiazolidinedione (TZD) with or without metformin.

      Objective

      This study was conducted to examine the long-term safety profile and changes in glycemic control and weight for exenatide once weekly with TZD with or without metformin in patients with type 2 diabetes mellitus over 2 years.

      Methods

      In this single-arm, open-label trial with treatment up to 104 or 117 weeks, patients received 2 mg exenatide once weekly while continuing treatment with a TZD with or without metformin. Patients were either exenatide-naïve before this study or had previously received exenatide twice daily, which was discontinued on initiating exenatide once weekly. Patients were on a stable dosage of TZD (rosiglitazone or pioglitazone) and, if applicable, metformin. Treatment-emergent AEs were defined as those first occurring or worsening post baseline. Descriptive statistics were used for absolute and change-from-baseline data, and a one-sample t test for within-group change in glycosylated hemoglobin (HbA1c).

      Results

      Of 134 patients in the intent-to-treat population (baseline mean [SD] HbA1c,7.2% [1.0%]), 44 were exenatide-naïve (baseline HbA1c, 7.8% [1.0%]) and 90 switched from exenatide twice daily (baseline HbA1c, 7.0% [0.8%]). Of intent-to-treat patients, 106 (79%) completed the final treatment visit (week 104 or week 117). The most common AEs were nausea (17% of patients) and injection-site nodule (12% of patients). Serious AEs were reported in 14% of patients and 5% withdrew because of a treatment-emergent AE. No identifiable pattern of serious AEs was observed. There were 4 reports of edema and no reports of heart failure. No major hypoglycemia was reported; minor hypoglycemia was reported in 4% of patients. Exenatide-naïve patients experienced mean (SE) HbA1c reductions of −0.7% (0.2%) and weight reductions of −2.7 (0.8) kg, whereas patients with prior exposure to exenatide twice daily experienced a reduction of −0.4% (0.1%) in HbA1c and no change in weight.

      Conclusions

      Adverse events over 2 years were consistent with the reported safety profiles of exenatide once weekly and TZDs. Exenatide-naïve patients experienced improvements in HbA1c and weight, while patients with the benefit of prior exenatide therapy experienced an additional reduction from baseline in HbA1c and no additional change in weight after 2 years. ClinicalTrials.gov identifier: NCT00753896.

      Key words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Clinical Therapeutics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Nielsen L.L.
        • Young A.A.
        • Parkes D.G.
        Pharmacology of exenatide (synthetic exendin-4): a potential therapeutic for improved glycemic control of type 2 diabetes.
        Regul Pept. 2004; 117: 77-88
        • Bergenstal R.M.
        • Wysham C.
        • MacConell L.
        • et al.
        • DURATION-2 Study Group
        Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial.
        Lancet. 2010; 376: 431-439
        • Blevins T.
        • Pullman J.
        • Malloy J.
        • et al.
        • DURATION-5 Study Group
        DURATION-5: exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes.
        J Clin Endocrinol Metab. 2011; 96: 1301-1310
        • Diamant M.
        • Van Gaal L.
        • Stranks S.
        • et al.
        • DURATION-3 Study Group
        Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial.
        Lancet. 2010; 375: 2234-2243
        • Drucker D.J.
        • Buse J.B.
        • Taylor K.
        • et al.
        • DURATION-1 Study Group
        Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study.
        Lancet. 2008; 372: 1240-1250
        • Russell-Jones D.
        • Cuddihy R.M.
        • Hanefeld M.
        • et al.
        • DURATION-4 Study Group
        Efficacy and safety of exenatide once weekly versus metformin, pioglitazone, and sitagliptin used as monotherapy in drug-naive patients with type 2 diabetes (DURATION-4): a 26-week double-blind study.
        Diabetes Care. 2012; 35: 252-258
        • MacConell L.
        • Brown C.
        • Gurney K.
        • Han J.
        Safety and tolerability of exenatide twice daily in patients with type 2 diabetes: integrated analysis of 5594 patients from 19 placebo-controlled and comparator-controlled clinical trials.
        Diabetes Metab Syndr Obes. 2012; 5: 29-41
        • DeFronzo R.A.
        Pharmacologic therapy for type 2 diabetes mellitus.
        Ann Intern Med. 1999; 131: 281-303
        • Samuel V.T.
        • Petersen K.F.
        • Shulman G.I.
        Lipid-induced insulin resistance: unravelling the mechanism.
        Lancet. 2010; 375: 2267-2277
        • Hernandez A.V.
        • Usmani A.
        • Rajamanickam A.
        • Moheet A.
        Thiazolidinediones and risk of heart failure in patients with or at high risk of type 2 diabetes mellitus: a meta-analysis and meta-regression analysis of placebo-controlled randomized clinical trials.
        Am J Cardiovasc Drugs. 2011; 11: 115-128
        • Berlie H.D.
        • Kalus J.S.
        • Jaber L.A.
        Thiazolidinediones and the risk of edema: a meta-analysis.
        Diabetes Res Clin Pract. 2007; 76: 279-289
        • Lago R.M.
        • Singh P.P.
        • Nesto R.W.
        Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials.
        Lancet. 2007; 370: 1129-1136
        • Nesto R.W.
        • Bell D.
        • Bonow R.O.
        • et al.
        Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association.
        October 7, 2003Circulation. 2003; 108: 2941-2948
        • Phung O.J.
        • Scholle J.M.
        • Talwar M.
        • Coleman C.I.
        Effect of noninsulin antidiabetic drugs added to metformin therapy on glycemic control, weight gain, and hypoglycemia in type 2 diabetes.
        JAMA. 2010; 303: 1410-1418
        • Nissen S.E.
        • Wolski K.
        Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes.
        N Engl J Med. 2007; 356: 2457-2471
        • Inzucchi S.E.
        • Bergenstal R.M.
        • Buse J.B.
        • et al.
        Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).
        Diabetes Care. 2012; 35: 1364-1379
        • Rodbard H.W.
        • Jellinger P.S.
        • Davidson J.A.
        • et al.
        Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control.
        Endocr Pract. 2009; 15: 540-559
        • Zinman B.
        • Hoogwerf B.J.
        • Durán García S.
        • et al.
        The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes: a randomized trial.
        Ann Intern Med. 2007; 146: 477-485
        • Liutkus J.
        • Rosas Guzman J.
        • Norwood P.
        • et al.
        A placebo-controlled trial of exenatide twice-daily added to thiazolidinediones alone or in combination with metformin.
        Diabetes Obes Metab. 2010; 12: 1058-1065
        • Pencek R.
        • Brunell S.C.
        • Li Y.
        • et al.
        Use of concomitant glucose-lowering therapies and associated treatment results observed in clinical trials of twice-daily exenatide.
        Endocr Pract. 2012; 18: 227-237
        • Norwood P.
        • Pintilei E.
        • Pop L.
        • et al.
        Safety of exenatide once weekly in patients with type 2 diabetes treated with a thiazolidinedione.
        Diabetes. 2010; 59 (Abstract 715-P)
      1. World Medical Association Declaration of Helsinki.
        JAMA. 1997; 277: 925-926
      2. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use.
        (Accessed April 3, 2012)
        • Diamant M.
        • Van Gaal L.
        • Stranks S.
        • et al.
        Safety and efficacy of once-weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes over 84 weeks.
        Diabetes Care. 2012; 35: 683-689
        • DeYoung M.B.
        • MacConell L.
        • Sarin V.
        • et al.
        Encapsulation of exenatide in poly-(D,L-lactide-co-glycolide) microspheres produced an investigational long-acting once-weekly formulation for type 2 diabetes.
        Diabetes Technol Ther. 2011; 13: 1145-1154
        • Kung J.
        • Henry R.R.
        Thiazolidinedione safety.
        Expert Opin Drug Saf. 2012; 11: 565-579
        • Jain R.
        • Mullins C.D.
        • Lee H.
        • Wong W.
        Use of rosiglitazone and pioglitazone immediately after the cardiovascular risk warnings.
        Res Social Adm Pharm. 2012; 8: 47-59
        • Hurren K.M.
        • Taylor T.N.
        • Jaber L.A.
        Antidiabetic prescribing trends and predictors of thiazolidine discontinuation following the 2007 rosigitazone safety alert.
        Diabetes Res Clin Pract. 2011; 93: 49-55
        • Vilsbøll T.
        • Christensen M.
        • Junker A.E.
        • et al.
        Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials.
        BMJ. 2012; 344: d7771
        • Zinman B.
        • Gerich J.
        • Buse J.B.
        • et al.
        Efficacy and safety of the human GLP-1 analog liraglutide in combination with metformin and TZD in patients with type 2 diabetes mellitus (LEAD-4 Met+TZD).
        Diabetes Care. 2009; 32: 1224-1230
        • Buse J.B.
        • Drucker D.J.
        • Taylor K.L.
        • et al.
        DURATION-1: exenatide once weekly produces sustained glycemic control and weight loss over 52 weeks.
        Diabetes Care. 2010; 33: 1255-1261